| [1] |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33. DOI: 10.3322/caac.21654.
doi: 10.3322/caac.21654
|
| [2] |
Rütten H, Verhoef C, van Weelden WJ, et al. Recurrent endome-trial cancer: local and systemic treatment options[J]. Cancers (Basel), 2021, 13(24): 6275. DOI: 10.3390/cancers13246275.
doi: 10.3390/cancers13246275
|
| [3] |
Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and posto-perative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma[J]. Lancet, 2000, 355(9213): 1404-1411. DOI: 10.1016/s0140-6736(00)02139-5.
doi: 10.1016/s0140-6736(00)02139-5
pmid: 10791524
|
| [4] |
徐兴远, 王丹波. 复发性子宫内膜癌的治疗[J]. 中国实用妇科与产科杂志, 2022, 38(5): 507-511. DOI: 10.19538/j.fk2022050108.
doi: 10.19538/j.fk2022050108
|
| [5] |
Sapienza LG, Ning MS, de la Pena R, et al. Outcomes and toxicity after salvage radiotherapy for vaginal relapse of endometrial cancer[J]. Int J Gynecol Cancer, 2020, 30(10): 1535-1541. DOI: 10. 1136/ijgc-2020-001281.
doi: 10.1136/ijgc-2020-001281
pmid: 32376738
|
| [6] |
Crosbie EJ, Kitson SJ, McAlpine JN, et al. Endometrial cancer[J]. Lancet, 2022, 399(10333): 1412-1428. DOI: 10.1016/S0140-6736(22)00323-3.
doi: 10.1016/S0140-6736(22)00323-3
pmid: 35397864
|
| [7] |
中国抗癌协会妇科肿瘤专业委员会. 子宫内膜癌诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6): 501-512. DOI: 10.19401/j.cnki.1007-3639.2021.06.08.
doi: 10.19401/j.cnki.1007-3639.2021.06.08
|
| [8] |
Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase Ⅲ trial (NRG oncology/GOG0209)[J]. J Clin Oncol, 2020, 38(33): 3841-3850. DOI: 10.1200/JCO.20. 01076.
doi: 10.1200/JCO.20.01076
pmid: 33078978
|
| [9] |
殷爱军, 李鹏, 宋坤, 等. 安罗替尼在妇科肿瘤治疗中的现状及研究进展[J]. 现代妇产科进展, 2022, 31(5): 384-388, 393. DOI: 10.13283/j.cnki.xdfckjz.2022.05.016.
doi: 10.13283/j.cnki.xdfckjz.2022.05.016
|
| [10] |
Cui Q, Mao Y, Hu Y, et al. Anlotinib in recurrent or metastatic endometrial cancer[J]. Int J Gynecol Cancer, 2022, 32: 1147-1152. DOI: 10.1136/ijgc-2022-003345.
doi: 10.1136/ijgc-2022-003345
|
| [11] |
Wei W, Ban X, Yang F, et al. Phase Ⅱ trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer[J]. J Immunother Cancer, 2022, 10(5): e004338. DOI: 10.1136/jitc-2021-004338.
doi: 10.1136/jitc-2021-004338
|
| [12] |
Taurin S, Yang CH, Reyes M, et al. Endometrial cancers harbo-ring mutated fibroblast growth factor receptor 2 protein are success-fully treated with a new small tyrosine kinase inhibitor in an orthotopic mouse model[J]. Int J Gynecol Cancer, 2018, 28(1): 152-160. DOI: 10.1097/IGC.0000000000001129.
doi: 10.1097/IGC.0000000000001129
|
| [13] |
Lin B, Song X, Yang D, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1[J]. Gene, 2018, 654: 77-86. DOI: 10.1016/j.gene.2018.02.026.
doi: S0378-1119(18)30155-0
pmid: 29454091
|
| [14] |
Jablonski S. Online endometrial cancer/anlotinib/anlotinib hydroch-loride[DB/OL]. Bethesda (MD): National Library of Medicine (US). (2021-11-30)[2022-8-12]. http://www.nlm.nih.gov.
|
), 叶斌强2
